stockmarketproxy
/
CYTKNasdaq SEC EDGAR

CYTOKINETICS INC

Pharmaceutical Preparations·SOUTH SAN FRANCISCO, CA·FY end 12/31·CIK 1061983
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$88.0M$18.5M$7.5M$94.6M$70.4M
Gross Profit——————
Operating Income-$612.3M-$536.2M-$496.2M-$324.2M-$186.3M
Net Income-$785.0M-$589.5M-$526.2M-$389.0M-$215.3M
Operating CF-$510.0M-$395.9M-$414.3M-$299.5M-$142.5M
Capex$24.8M$3.9M$1.4M$11.3M$48.9M
Free Cash Flow-$534.8M-$399.8M-$415.7M-$310.9M-$191.4M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin-695.4%-2902.7%-6589.7%-342.8%-264.5%
Net Margin-891.6%-3191.1%-6988.6%-411.2%-305.7%
FCF Margin-607.5%-2164.1%-5521.2%-328.6%-271.8%
R&D / Revenue472.5%1837.2%4384.1%254.6%227.1%
Effective Tax——————
Debt / Equity-0.37-5.27-1.81-6.610.19
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
CYTK
28:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
CYTK
$12M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
CYTK
-891.6%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%